We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Fate Therapeutics (FATE) USD0.001

Sell:$37.00 Buy:$50.29 Change: $4.60 (8.75%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$37.00
Buy:$50.29
Change: $4.60 (8.75%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$37.00
Buy:$50.29
Change: $4.60 (8.75%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an ideal source for creating cell therapy product candidates. The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573.

Contact details

Address:
12278 Scripps Summit Drive
SAN DIEGO
92131
United States
Telephone:
+1 (858) 8751803
Website:
fatetherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FATE
ISIN:
US31189P1021
Market cap:
$4.98 billion
Shares in issue:
95.49 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Wolchko
    President, Chief Executive Officer, Director
  • Edward Dulac
    Chief Financial Officer
  • Yu-Waye Chu
    Senior Vice President - Clinical Development
  • Mark Plavsic
    Chief Technology Officer
  • Cindy Tahl
    General Counsel and Corporate Secretary
  • Bahram Valamehr
    Chief Research and Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.